For example, the dual PI3K/mTOR inhibitor NVP-BEZ235 (Novartis) is an orally bioavailable reagent that was reported to inhibit tumor growth in many preclinical models, and it enhanced the antitumor activity of several other cancer drugs. This evidence concerns the gene PIK3CA and neoplasm.